HRP20220519T1 - Kombinacijska terapija ishemije - Google Patents
Kombinacijska terapija ishemije Download PDFInfo
- Publication number
- HRP20220519T1 HRP20220519T1 HRP20220519TT HRP20220519T HRP20220519T1 HR P20220519 T1 HRP20220519 T1 HR P20220519T1 HR P20220519T T HRP20220519T T HR P20220519TT HR P20220519 T HRP20220519 T HR P20220519T HR P20220519 T1 HRP20220519 T1 HR P20220519T1
- Authority
- HR
- Croatia
- Prior art keywords
- psd
- inhibitor
- ischemia
- intended
- accordance
- Prior art date
Links
- 208000028867 ischemia Diseases 0.000 title claims 19
- 238000002648 combination therapy Methods 0.000 title 1
- 229940123119 PSD-95 Inhibitor Drugs 0.000 claims 24
- 230000010410 reperfusion Effects 0.000 claims 19
- 238000002560 therapeutic procedure Methods 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000003527 fibrinolytic agent Substances 0.000 claims 7
- 229960000103 thrombolytic agent Drugs 0.000 claims 7
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims 5
- 102000047174 Disks Large Homolog 4 Human genes 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000000254 damaging effect Effects 0.000 claims 4
- 206010061216 Infarction Diseases 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 230000007574 infarction Effects 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 238000002591 computed tomography Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010023197 Streptokinase Proteins 0.000 claims 1
- 108010046423 Tat-NR2B9c Proteins 0.000 claims 1
- 108010039185 Tenecteplase Proteins 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229960003318 alteplase Drugs 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- XWQVQFBTSBCKLI-FKXNDIMNSA-N dnc008987 Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XWQVQFBTSBCKLI-FKXNDIMNSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000008384 membrane barrier Effects 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229960002917 reteplase Drugs 0.000 claims 1
- 108010051412 reteplase Proteins 0.000 claims 1
- 229960005202 streptokinase Drugs 0.000 claims 1
- 229960000216 tenecteplase Drugs 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Dermatology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
Claims (18)
1. Inhibitor PSD-95, naznačen time što je namijenjen upotrebi u liječenju oštećujućeg učinka ishemije na središnji živčani sustav kod subjekta koji ima ili je u opasnosti od ishemije, gdje se reperfuzijsku terapiju provodi na subjektu, a inhibitor PSD-95 i reperfuzijska terapija liječe oštećujući učinak ishemije na središnji živčani sustav subjekta, te gdje se reperfuzijska terapija sastoji u primjeni trombolitičkog sredstva, gdje inhibitor PSD-95 sadrži peptid koji sadrži SEQ ID NO:38 na C-kraju, ili sadrži SEQ ID NO:68, gdje je peptid vezan na internalizirajući peptid ili je lipidiran, čime se pojačava prolazak peptida preko membrane ili krvno-moždane barijere.
2. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se inhibitor PSD-95 primjenjuje kada se sumnja na inzult ili koje drugo ishemijsko stanje bez postavljanja dijagnoze u skladu s kriterijima prepoznatima u struci.
3. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se primjenjuje unutar 15 minuta nakon trombolitičkog sredstva.
4. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen primjeni u više doza dok se ne detektira prisutnost potpunog infarkta prilikom CT skeniranja ili dok se ne vidi nikakva daljnja dobrobit.
5. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je oštećujući učinak ishemije infarkt ili funkionalni nedostatak.
6. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se inhibitor PSD-95 primjenjuje prije provođenja reperfuzijske terapije, ili se inhibitor PSD-95 primjenjuje na subjektu u opasnosti od ishemije prije početka ishemije i provođenje reperfuzijske terapije nakon početka ishemije, ili se inhibitor PSD-95 primjenjuje i reperfuzijsku terapiju provodi nakon početka ishemije.
7. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je ishemija cerebralna ishemija, ili što subjekt ima inzult, ili što je ishemija srčana, plućna ili velika ishemija udova, koja pogađa središnji živčani sustav inhibiranjem krvotoka u ili iz CNS-a.
8. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se subjekta testira na prisutnost cerebralne ishemije i/ili odsutnost cerebralnog krvarenja između primjene inhibitora PSD-95 i provođenja reperfuzijske terapije, ili što se subjekta procjenjuje na prisutnost ili opasnost od krvarenja između primjene inhibitora PSD-95 i provođenja reperfuzijske terapije, izborno što procjenjivanje uključuje provođenje PET skeniranja, CAT skeniranja, MRI, ili pregledavanje povijesti subjektove bolesti, ili upotrebu jednog ili više bioloških biljega koji ukazuju na ishemiju.
9. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je inhibitor PSD-95 vezan na internalizirajući peptid Tat kako bi tvorio Tat-NR2B9c.
10. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je trombolitičko sredstvo aktivator plazminogena.
11. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je trombolitičko sredstvo tPA, primjerice alteplaza, reteplaza ili tenekteplaza.
12. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je trombolitičko sredstvo streptokinaza, urokinaza, ili dezmotaplaza.
13. Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 9-12, naznačen time što je interval između primjene inhibitora PSD-95 i reperfuzijske terapije 30 minuta do 6 sati, ili što se reperfuzijsku terapiju provodi više od 3 sata nakon početka ishemije.
14. Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 9-13, naznačen time što se trombolitičko sredstvo primjenjuje lokaliziranom primjenom na mjestu smanjenog krvotoka, ili što se reperfuzijsku terapiju provodi više od 3 sata nakon početka ishemije, što se reperfuzijsku terapiju izborno provodi više od 4,5 sati nakon početka ishemije, ili što se reperfuzijsku terapiju provodi više od 4,5 sati, a manje od 24 sata nakon početka ishemije.
15. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što provođenje reperfuzijske terapije nakon određivanja ima li kod subjekta razloga za reperfuziju na osnovi neočitovanja potpunog infarkta, ishemijske penumbre i neočitovanja krvarenja prilikom CT, MRI ili PET analize, ili što se reperfuzijsku terapiju provodi najmanje 12 ili najmanje 24 sata nakon početka ishemije, ili što se reperfuzijsku terapiju provodi 275-690 minuta nakon početka ishemije.
16. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je peptid lipidiran kao miristoilirani peptid, što pojačava prolazak peptida preko stanične membrane ili krvno-moždane barijere.
17. Inhibitor PSD-95, namijenjen upotrebi u skladu s patentnim zahtjevom 16, naznačen time što peptid ima aminokiselina slijed koji se sastoji od ili sadrži KLSSIESDV (SEQ ID NO:5) ili KLSSIETDV (SEQ ID NO:43), izborno miristoiliran na N-kraju peptida.
18. Trombolitičko sredstvo, naznačeno time što je namijenjeno upotrebi u reperfuzijskoj terapiji kod subjekta koji također prima inhibitor PSD-95, gdje reperfuzijska terapija i sredstvo liječe oštećujući učinak ishemije na središnji živčani sustav, gdje inhibitor PSD-95 sadrži peptid koji sadrži SEQ ID NO:38 na C-kraju, ili sadrži SEQ ID NO:68, gdje je peptid vezan na internalizirajući peptid ili je lipidiran, čime se pojačava prolazak peptida preko membrane ili krvno-moždane barijere.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501117P | 2011-06-24 | 2011-06-24 | |
| US201261617001P | 2012-03-28 | 2012-03-28 | |
| EP18190827.8A EP3427748B1 (en) | 2011-06-24 | 2012-06-23 | Combination therapy for ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220519T1 true HRP20220519T1 (hr) | 2022-05-27 |
Family
ID=47423033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220519TT HRP20220519T1 (hr) | 2011-06-24 | 2012-06-23 | Kombinacijska terapija ishemije |
| HRP20181526TT HRP20181526T1 (hr) | 2011-06-24 | 2018-09-25 | Kombinacijska terapija ishemije |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181526TT HRP20181526T1 (hr) | 2011-06-24 | 2018-09-25 | Kombinacijska terapija ishemije |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10064910B2 (hr) |
| EP (3) | EP4052721A1 (hr) |
| JP (5) | JP6401057B2 (hr) |
| KR (5) | KR102425466B1 (hr) |
| CN (1) | CN103648518B (hr) |
| AU (1) | AU2012274910B2 (hr) |
| CA (1) | CA2839630A1 (hr) |
| CY (1) | CY1121379T1 (hr) |
| DK (2) | DK2723363T3 (hr) |
| ES (2) | ES2912042T3 (hr) |
| HR (2) | HRP20220519T1 (hr) |
| HU (2) | HUE040564T2 (hr) |
| LT (1) | LT2723363T (hr) |
| PL (2) | PL2723363T3 (hr) |
| PT (2) | PT3427748T (hr) |
| RS (1) | RS57798B1 (hr) |
| SI (1) | SI2723363T1 (hr) |
| WO (1) | WO2012176172A2 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458441A (zh) | 2009-06-10 | 2012-05-16 | 诺诺公司 | 用于治疗神经疾病的模型系统和治疗方案 |
| DK2723363T3 (en) | 2011-06-24 | 2018-10-15 | Nono Inc | COMBINATION THERAPY AGAINST CREAM |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| CZ2012476A3 (cs) * | 2012-07-12 | 2014-01-22 | Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. | Lipidované peptidy jako antiobezitika |
| US10220008B2 (en) | 2013-08-14 | 2019-03-05 | Stc.Unm | Treatment and prevention of stroke and other neurological disorders |
| EP3074030A4 (en) * | 2013-11-26 | 2017-08-16 | Trustees of Dartmouth College | Method for mitigating or alleviating synaptic and cognitive deficits |
| FR3021319B1 (fr) * | 2014-05-22 | 2018-08-31 | Sederma | Peptides, compositions les comprenant et utilisations notamment cosmetiques |
| CZ309217B6 (cs) * | 2014-05-27 | 2022-06-01 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | Lipidované peptidy jako neuroprotektiva |
| AU2015265487B2 (en) * | 2014-05-28 | 2020-08-13 | Nono Inc. | Chloride salt of TAT-NR2B9c |
| US9526768B2 (en) | 2014-11-13 | 2016-12-27 | Jennifer Mai | Compositions for the treatment of cancer |
| CN104497106B (zh) * | 2014-12-05 | 2017-05-10 | 华中科技大学 | 一种小分子多肽、其应用及产品 |
| CN107312069B (zh) * | 2016-04-27 | 2018-11-06 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽 |
| US11229675B2 (en) | 2016-04-27 | 2022-01-25 | Biocells (Beijing) Biotech Co., Ltd. | Therapeutic peptides for excitatory neurotoxicity-related injuries |
| WO2017185250A1 (zh) * | 2016-04-27 | 2017-11-02 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗方法 |
| CN107446016A (zh) * | 2016-05-30 | 2017-12-08 | 上海交通大学 | 一种硬脂酸修饰的细胞穿膜肽及其制备与应用 |
| CN106265594B (zh) * | 2016-09-21 | 2019-07-26 | 南京医科大学 | 一种缺血性脑卒中靶向的红细胞膜仿生智能药物载体及其制备方法 |
| CN106749559B (zh) * | 2016-11-23 | 2020-09-04 | 郑州大学 | 一种基于细胞穿膜肽Tat(49-57)的抗菌肽及其合成方法 |
| JP7109958B2 (ja) * | 2017-04-04 | 2022-08-01 | キヤノンメディカルシステムズ株式会社 | 磁気共鳴イメージングシステム、磁気共鳴イメージング装置、及び磁気共鳴イメージング方法 |
| CN110799522B (zh) * | 2017-07-05 | 2023-08-29 | 拜西欧斯（北京）生物技术有限公司 | 用于治疗、改善或预防脑出血的肽及其用途 |
| BR112020000115A2 (pt) * | 2017-07-05 | 2020-07-07 | Biocells (Beijing) Biotech Co., Ltd. | sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos |
| BR112020006321A2 (pt) | 2017-09-30 | 2020-11-17 | Biocells (Beijing) Biotech Co., Ltd. | composição de peptídeos para tratamento de lesões relacionadas a neurotoxicidade excitatória |
| WO2019195741A1 (en) * | 2018-04-06 | 2019-10-10 | Northwestern University | Bdnf mimetic peptide amphiphiles |
| JP7158904B2 (ja) * | 2018-06-14 | 2022-10-24 | 社会福祉法人 恩賜財団済生会熊本病院 | 治療方針決定支援装置、治療方針決定支援装置の作動方法、および治療方針決定支援プログラム |
| JP2023514394A (ja) * | 2020-02-19 | 2023-04-05 | ノノ インコーポレイテッド | プラスミンで切断可能なｐｓｄ－９５阻害剤及び再灌流を用いる脳卒中の併用療法 |
| EP4106818A4 (en) * | 2020-02-19 | 2024-03-20 | Nono Inc | INHIBITION OF REPERFUSION INJURY WITH A PSD-95 INHIBITOR |
| CN113735938A (zh) * | 2021-07-30 | 2021-12-03 | 英纳氏(珠海)药业有限公司 | 一种神经保护多肽化合物及其应用 |
| WO2023192848A1 (en) * | 2022-03-28 | 2023-10-05 | University Of Maryland, Baltimore | Methods and compositions for the treatment of stroke |
| CN117422722B (zh) * | 2023-12-19 | 2024-03-29 | 北京智源人工智能研究院 | 基于adc图像的肿瘤预后特征评估的方法和装置 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2742152B1 (fr) | 1995-12-06 | 1998-01-16 | Synthelabo | Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique |
| US6562345B1 (en) | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6903184B1 (en) | 1998-03-02 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multiple antigenic peptides immunogenic against Streptococcus pneumonia |
| US20060148711A1 (en) | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
| CA2523565A1 (en) | 2003-04-25 | 2004-11-11 | Mitos Incorporated | Prophylactic pretreatment with antioxidants |
| CA2524573A1 (en) | 2003-05-02 | 2004-11-11 | Paion Deutschland Gmbh | Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke |
| CN1946416A (zh) * | 2003-05-19 | 2007-04-11 | 肯尼思S·沃伦协会有限公司 | 用于保护、恢复和增强效应细胞、组织和器官具有延迟的治疗窗口的组织保护性细胞因子 |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| US8685925B2 (en) | 2006-07-11 | 2014-04-01 | Nono Inc. | Method and compositions for treating stroke with fever |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| CU23630A1 (es) | 2006-10-30 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae |
| DK2120987T3 (en) | 2007-03-02 | 2014-02-24 | Nono Inc | Treatment of stroke and other diseases without inhibiting N-type calcium channels |
| GB0707348D0 (en) | 2007-04-17 | 2007-05-23 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| WO2009006611A1 (en) | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| US8071555B2 (en) | 2007-10-29 | 2011-12-06 | Helix Biomedix Inc. | Protective skin care peptides |
| US8933013B2 (en) | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| US8653020B2 (en) | 2008-01-25 | 2014-02-18 | Aarhus Universitet | Selective exosite inhibition of PAPP-A activity against IGFBP-4 |
| DK2320927T3 (en) | 2008-07-09 | 2015-09-14 | Univ Copenhagen | Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction |
| DE102008037564A1 (de) | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| CA2665302A1 (en) | 2009-05-01 | 2010-11-01 | Universite De Montreal | Cd36 modulation and uses thereof |
| CN102458441A (zh) | 2009-06-10 | 2012-05-16 | 诺诺公司 | 用于治疗神经疾病的模型系统和治疗方案 |
| US20110144029A1 (en) | 2009-09-30 | 2011-06-16 | Board Of Regents, The University Of Texas System | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases |
| DK2723363T3 (en) | 2011-06-24 | 2018-10-15 | Nono Inc | COMBINATION THERAPY AGAINST CREAM |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| DK2800575T3 (da) | 2011-12-13 | 2019-07-01 | Nono Inc | Behandling af subarachnoidalblødning og iskæmi |
-
2012
- 2012-06-23 DK DK12802409.8T patent/DK2723363T3/en active
- 2012-06-23 CA CA2839630A patent/CA2839630A1/en active Pending
- 2012-06-23 CN CN201280031302.4A patent/CN103648518B/zh active Active
- 2012-06-23 KR KR1020217026955A patent/KR102425466B1/ko active IP Right Grant
- 2012-06-23 WO PCT/IB2012/053178 patent/WO2012176172A2/en active Application Filing
- 2012-06-23 RS RS20181182A patent/RS57798B1/sr unknown
- 2012-06-23 EP EP22157256.3A patent/EP4052721A1/en active Pending
- 2012-06-23 PT PT181908278T patent/PT3427748T/pt unknown
- 2012-06-23 LT LTEP12802409.8T patent/LT2723363T/lt unknown
- 2012-06-23 PT PT12802409T patent/PT2723363T/pt unknown
- 2012-06-23 PL PL12802409T patent/PL2723363T3/pl unknown
- 2012-06-23 HR HRP20220519TT patent/HRP20220519T1/hr unknown
- 2012-06-23 EP EP12802409.8A patent/EP2723363B1/en active Active
- 2012-06-23 SI SI201231412T patent/SI2723363T1/sl unknown
- 2012-06-23 KR KR1020197026571A patent/KR102140169B1/ko active IP Right Grant
- 2012-06-23 ES ES18190827T patent/ES2912042T3/es active Active
- 2012-06-23 US US14/128,941 patent/US10064910B2/en active Active
- 2012-06-23 KR KR1020147001639A patent/KR102022116B1/ko active IP Right Grant
- 2012-06-23 PL PL18190827T patent/PL3427748T3/pl unknown
- 2012-06-23 HU HUE12802409A patent/HUE040564T2/hu unknown
- 2012-06-23 EP EP18190827.8A patent/EP3427748B1/en active Active
- 2012-06-23 AU AU2012274910A patent/AU2012274910B2/en active Active
- 2012-06-23 DK DK18190827.8T patent/DK3427748T3/da active
- 2012-06-23 JP JP2014516487A patent/JP6401057B2/ja active Active
- 2012-06-23 HU HUE18190827A patent/HUE058238T2/hu unknown
- 2012-06-23 KR KR1020207021829A patent/KR102296106B1/ko active IP Right Grant
- 2012-06-23 KR KR1020227025470A patent/KR20220106862A/ko not_active Application Discontinuation
- 2012-06-23 ES ES12802409.8T patent/ES2690994T3/es active Active
-
2017
- 2017-04-05 JP JP2017074975A patent/JP2017193535A/ja active Pending
-
2018
- 2018-08-01 US US16/051,971 patent/US10967041B2/en active Active
- 2018-09-25 HR HRP20181526TT patent/HRP20181526T1/hr unknown
- 2018-10-30 JP JP2018204034A patent/JP7085457B2/ja active Active
- 2018-11-28 CY CY20181101260T patent/CY1121379T1/el unknown
-
2020
- 2020-08-06 JP JP2020134150A patent/JP7143374B2/ja active Active
-
2021
- 2021-02-17 US US17/177,970 patent/US11878044B2/en active Active
-
2022
- 2022-09-14 JP JP2022146191A patent/JP2022188068A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220519T1 (hr) | Kombinacijska terapija ishemije | |
| Wasserman et al. | Minocycline protects the blood–brain barrier and reduces edema following intracerebral hemorrhage in the rat | |
| Keep et al. | Blood-brain barrier function in intracerebral hemorrhage | |
| Hausenloy et al. | Myocardial ischemia-reperfusion injury: a neglected therapeutic target | |
| JP2014520142A5 (hr) | ||
| Yellon et al. | Myocardial reperfusion injury | |
| HRP20201973T1 (hr) | Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti | |
| Fann et al. | Pathogenesis of acute stroke and the role of inflammasomes | |
| Savitz et al. | Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials | |
| Yang et al. | Dl-3-n-butylphthalide reduces neurovascular inflammation and ischemic brain injury in mice | |
| JP2016500648A5 (hr) | ||
| Simkhada et al. | Purification, biochemical properties and antithrombotic effect of a novel Streptomyces enzyme on carrageenan-induced mice tail thrombosis model | |
| JP2014511698A5 (hr) | ||
| JP2012523438A5 (hr) | ||
| Shevtsov et al. | Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats | |
| WO2009126349A3 (en) | Methods and compositions related to internalizing rgd peptides | |
| Gauberti et al. | Thrombolytic strategies for ischemic stroke in the thrombectomy era | |
| Kassis et al. | Class IIa histone deacetylases affect neuronal remodeling and functional outcome after stroke | |
| Sonni et al. | New avenues for treatment of intracranial hemorrhage | |
| JP2015522264A5 (hr) | ||
| Singh et al. | Valproic acid in prevention and treatment of COVID-19 | |
| Elbadawi et al. | Impact of remote ischemic postconditioning during primary percutaneous coronary intervention on left ventricular remodeling after anterior wall ST-segment elevation myocardial infarction: a single-center experience | |
| Smith et al. | Salmon-derived thrombin inhibits development of chronic pain through an endothelial barrier protective mechanism dependent on APC | |
| Rong et al. | Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by κ-opioid receptor agonist | |
| Zhu et al. | Curcumin alleviates hepatic ischemia-reperfusion injury by inhibiting neutrophil extracellular traps formation |